Mediar Therapeutics

Founded 2018 · CIK 0001766784 · Biotech · Private

Small molecule therapeutics platform targeting novel fibrotic pathways for idiopathic pulmonary fibrosis (IPF)

mediartx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$75M
3 Form D · Dec 2025
10 months since last filing
Contracts
—
No federal contracts on record
Patents
7
0 granted · 7 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$5,000,000
Private capital raisedForm D · SEC$31,761,186
Private capital raisedForm D · SEC$37,849,815
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1262Young Biopharma, LLC——
1263Proteovant Therapeutics——
1264Pelthos Therapeutics Inc.—$69M
1265Mediar Therapeutics—$75M
1266MOLECULAR TECHNOLOGIES LABORATORIES LLC——
1267MARTINGALE LABS, INC.——
1268Monte Rosa Therapeutics, Inc.—$143M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 17 related persons
  • Rahul BallalDirector · Executive Officer
  • Michael BaranDirector
  • Maina BhamanDirector
  • Cassidy BlundellDirector
  • Stacey BrennerExecutive Officer
  • Adam CottonDirector
  • David de GraafDirector
  • Meredith FisherDirector · Executive Officer
  • Brian HubbardDirector
  • Andreas JurgeitDirector
  • Anja KonigDirector
  • Allan MarchingtonDirector
  • Peter ParkerDirector
  • Marie-Claire PeakmanDirector
  • Nandita ShangariDirector
  • Bharat SrinivasaDirector
  • Simon SturgeDirector

Patents

USPTO · 0 granted of 7
  • Anti-ephrin B2 Antibodies And Methods Of Useapplication
  • ANTI-WISP1 Antibodies And Methods Of Useapplication
  • Therapeutic Antibody Targeting WISP1 Proteinapplication
  • Therapeutic Antibody Targeting WISP1 Proteinapplication
  • Anti-ephrin B2 Antibodies And Methods Of Useapplication
  • Therapeutic Antibody Targeting WISP1 Proteinapplication
  • ANTI-WISP1 Antibodies And Methods Of Useapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.